Confluent Health Strengthens National Network with Addition of Commonwealth Hand & Physical Therapy
LOUISVILLE, Ky., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Confluent Health, a national leader in musculoskeletal (MSK) care, today announced its...
LOUISVILLE, Ky., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Confluent Health, a national leader in musculoskeletal (MSK) care, today announced its...
On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026 TRX319 is an allogeneic CAR-Tr1 Treg cell therapy...
Late breaking session to feature results from the successful PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract...
– Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI®...
Once-daily Precision Timed Release™ (PTR™) stimulant designed to deliver rapid onset of effect and entire active-day duration NDA accepted under the...
Award recognizes technology breakthroughs that promise to help define the future of their industriesNEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE)...
Company outlines decisive initiatives to strengthen its dental and medical businesses, reduce operating expenses across the organization, and position Milestone...
Notification has no immediate effect on the Company’s listing or day-to-day operationsROSELAND, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Milestone...
MISSION VIEJO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Human Appeal joins the wider humanitarian community in welcoming the recently...
Milestone strengthens the company’s leadership in advanced IOL innovationFINEVISION HP, with millions of implantations worldwide, will now be available to...
Greater than 90% depletion of B cells within 12 hours of a single dose of AAN-14xMultiple redosing of AAN-14x at...
- Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and...
SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the design and...
– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst’s HAE...
Distinguished cancer leader to advise BPGbio leadership on acceleration of NAi platform globally and BPM 31510 oncology franchise for Precision...
Non-inferiority trial versus PAXLOVID® assessing safety and efficacy, including rates of disease rebound and incidence of Long COVID development, of...
SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to...
The FDA-approved wearable offers a drug-free, safe solution for treating nasal congestion and allergies.SAN FRANCISCO--(BUSINESS WIRE)--SoundHealth is proud to announce...
Next-Generation solution supports the NHS 10-year Health Plan and the mission to create a workforce that is fit for the...
Automation-compatible, safe assay delivers same-day results to accelerate vaccine and therapeutic antibody development PHILADELPHIA, Oct. 14, 2025 /PRNewswire/ -- Integral...